Tveter KJ - Search Results

1

Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer Group Study No. 2 (SPCG-2).

Jørgensen T, Müller C, Kaalhus O, Danielsen HE, Tveter KJ. Jørgensen T, et al. Among authors: tveter kj. Eur Urol. 1995;28(1):40-6. doi: 10.1159/000475018. Eur Urol. 1995. PMID: 8521893 Clinical Trial.

2

Total androgen suppression: experience from the Scandinavian Prostatic Cancer Group Study No. 2.

Jørgensen T, Tveter KJ, Jørgensen LH. Jørgensen T, et al. Among authors: tveter kj. Eur Urol. 1993;24(4):466-70. doi: 10.1159/000474351. Eur Urol. 1993. PMID: 8287887 Clinical Trial.

3

Nuclear texture analysis: a new prognostic tool in metastatic prostate cancer.

Jørgensen T, Yogesan K, Tveter KJ, Skjørten F, Danielsen HE. Jørgensen T, et al. Among authors: tveter kj. Cytometry. 1996 Jul 1;24(3):277-83. doi: 10.1002/(SICI)1097-0320(19960701)24:3<277::AID-CYTO11>3.0.CO;2-N. Cytometry. 1996. PMID: 8800561 Free article.

4

[Maximal androgen blockade in metastatic prostatic carcinoma].

Jørgensen T, Tveter KJ. Jørgensen T, et al. Among authors: tveter kj. Tidsskr Nor Laegeforen. 1997 Jan 30;117(3):381-3. Tidsskr Nor Laegeforen. 1997. PMID: 9064862 Review. Norwegian.

5

Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2.

Jørgensen T, Kanagasingam Y, Kaalhus O, Tveter KJ, Bryne M, Skjørten F, Berner A, Danielsen HE. Jørgensen T, et al. Among authors: tveter kj. J Urol. 1997 Jul;158(1):164-70. doi: 10.1097/00005392-199707000-00052. J Urol. 1997. PMID: 9186346 Clinical Trial.

6

Up-regulation of the oligosaccharide sialyl LewisX: a new prognostic parameter in metastatic prostate cancer.

Jørgensen T, Berner A, Kaalhus O, Tveter KJ, Danielsen HE, Bryne M. Jørgensen T, et al. Among authors: tveter kj. Cancer Res. 1995 May 1;55(9):1817-9. Cancer Res. 1995. PMID: 7728744

7

Histopathological grading and DNA ploidy as prognostic markers in metastatic prostatic cancer.

Jørgensen T, Yogesan K, Skjørten F, Berner A, Tveter KJ, Danielsen HE. Jørgensen T, et al. Among authors: tveter kj. Br J Cancer. 1995 May;71(5):1055-60. doi: 10.1038/bjc.1995.203. Br J Cancer. 1995. PMID: 7734299 Free PMC article.

8

Entropy-based texture analysis of chromatin structure in advanced prostate cancer.

Yogesan K, Jørgensen T, Albregtsen F, Tveter KJ, Danielsen HE. Yogesan K, et al. Among authors: tveter kj. Cytometry. 1996 Jul 1;24(3):268-76. doi: 10.1002/(SICI)1097-0320(19960701)24:3<268::AID-CYTO10>3.0.CO;2-O. Cytometry. 1996. PMID: 8800560 Free article.

9

A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia.

Eri LM, Tveter KJ. Eri LM, et al. Among authors: tveter kj. J Urol. 1993 Jul;150(1):90-4. doi: 10.1016/s0022-5347(17)35406-x. J Urol. 1993. PMID: 7685428 Clinical Trial.

10

Long-term survival and morbidity in patients with metastatic malignant germ cell tumors treated with cisplatin-based combination chemotherapy.

Fosså SD, Aass N, Kaalhus O, Klepp O, Tveter K. Fosså SD, et al. Cancer. 1986 Dec 15;58(12):2600-5. doi: 10.1002/1097-0142(19861215)58:12<2600::aid-cncr2820581208>3.0.co;2-d. Cancer. 1986. PMID: 3022908

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

136 results

Search Page

Filters